Real-World Evaluation of the Safety and Effectiveness of Apixaban & Rivaroxaban Lead-in Dosing Compared to Parenteral Lead-in Dosing in the Treatment of Venous Thromboembolism: A Multi-Center Retrospective Cohort Study

Background Although parenteral anticoagulation lead-in is not recommended with apixaban and rivaroxaban, parenteral anticoagulation is often used to replace apixaban or rivaroxaban lead-in doses for the initial phase treatment of VTE. Thus, our study compares the safety and effectiveness of lead-in parenteral anticoagulation to lead-in apixaban or rivaroxaban in patients who received apixaban or rivaroxaban for VTE treatment. Methods A multi-center retrospective cohort study included adult patients (aged ≥ 18 years) admitted to the hospital with acute VTE and treated with either apixaban or rivaroxaban. Patients were grouped depending on the lead-in anticoagulation received for initial VTE treatment into the “Direct oral anticoagulation (DOAC) lead-in” group if patients received an appropriate lead-in dose of apixaban and rivaroxaban and patients who received parenteral lead-in the “parenteral lead-in” group. Results A total of 389 patients were included; the DOAC lead-in group included 296 patients, whereas 93 patients were in the parenteral lead-in group. VTE recurrence (rVTE) during hospitalization and within 30 days was numerically higher in the parenteral lead-in group compared to the DOAC lead-in group (3.3% vs 0.6%; p=0.09 and 1.1% vs 0.7%; p=0.560), with a significantly higher number of patients with rVTE at 90 days (5.4% vs 1.4%; p=0.039). However, none of the patient’s characteristics were significantly associated with the incidence of rVTE. In addition, the major bleeding rate during hospitalization was significantly higher among the parenteral lead-in group than in the DOAC lead-in group (14.0% vs 3.7%; p<0.001). Conclusion Parenteral anticoagulation lead-in before starting maintenance of apixaban and rivaroxaban showed a significantly higher risk of bleeding and a trend toward higher VTE recurrence than the DOAC lead-in. This study adds to the evidence supporting the utilization of the DOAC lead-in regimen in treating patients with VTE. Still, larger studies with robust designs are needed to confirm these findings.

[1]  J. Papadopoulos,et al.  Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients , 2022, Journal of Thrombosis and Thrombolysis.

[2]  M. Cameli,et al.  Venous Thromboembolism and Cancer: A Comprehensive Review from Pathophysiology to Novel Treatment , 2022, Biomolecules.

[3]  S. Stevens,et al.  Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report - Executive Summary. , 2021, Chest.

[4]  S. Stevens,et al.  Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. , 2021, Chest.

[5]  W. Ageno,et al.  American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. , 2020, Blood advances.

[6]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[7]  Alfredo E Farjat,et al.  Anticoagulation therapy patterns for acute treatment of venous thromboembolism in GARFIELD‐VTE patients , 2019, Journal of thrombosis and haemostasis : JTH.

[8]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) , 2019, European Respiratory Journal.

[9]  W. Ageno,et al.  Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. , 2017, Thrombosis research.

[10]  W. Ageno,et al.  Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. , 2016, The Lancet. Haematology.

[11]  J. Ansell,et al.  Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment , 2016, Journal of Thrombosis and Thrombolysis.

[12]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[13]  J. Weitz,et al.  Evolving use of new oral anticoagulants for treatment of venous thromboembolism. , 2014, Blood.

[14]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[15]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[16]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[17]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[18]  S. Goldhaber,et al.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism. , 2009, The New England journal of medicine.

[19]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. , 2007, Haematologica.

[20]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[21]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[22]  M. Prins,et al.  Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. , 1999, Archives of internal medicine.